IC14 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	5

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04390386 (ClinicalTrials.gov)	January 1, 2021	13/5/2020	Controlled Study of IC14 for Treatment of ALS	Amyotrophic Lateral Sclerosis Trial: A Randomized, Double-Blind, Placebo-Controlled Study: IC14, a M ...	Amyotrophic Lateral Sclerosis	Biological: IC14;Other: Placebo	Implicit Bioscience	NULL	Withdrawn	18 Years	70 Years	All	0	Phase 2	United States
2	NCT04309604 (ClinicalTrials.gov)	October 18, 2019	12/3/2020	IC14 for ALS Patients Expanded Access	IC14 for ALS Patients Expanded Access	Amyotrophic Lateral Sclerosis	Biological: IC14	Implicit Bioscience	Massachusetts General Hospital	No longer available	18 Years	N/A	All			United States
3	NCT03474263 (ClinicalTrials.gov)	September 1, 2019	9/3/2018	IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)	A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With	Amyotrophic Lateral Sclerosis	Biological: Biologic: IC14 (monoclonal antibody against human CD14)	Implicit Bioscience	NULL	Withdrawn	18 Years	80 Years	All	0	Phase 2	Australia;United States
4	NCT03508453 (ClinicalTrials.gov)	August 15, 2019	16/4/2018	IC14 for Treatment of Amyotrophic Lateral Sclerosis	A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study of IC14for Treatment of Patients With ...	Amyotrophic Lateral Sclerosis;Motor Neuron Disease	Biological: IC14;Other: Placebo	Implicit Bioscience	NULL	Withdrawn	18 Years	75 Years	All	0	Phase 2	Australia
5	NCT03487263 (ClinicalTrials.gov)	October 1, 2017	9/3/2018	Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease	A Phase 1b, Open-Label, Dose-Escalation, Safety and Pharmacokinetic Study of IC14in Motor Neurone Di ...	Motor Neuron Disease;Amyotrophic Lateral Sclerosis	Biological: IC14	Implicit Bioscience	Royal Brisbane and Women's Hospital	Completed	18 Years	75 Years	All	10	Phase 1	Australia

First Previous1Next Last